La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will provide a corporate overview at the Jefferies 2016 Global Healthcare Conference taking place June 7–10 in New York City.

Jefferies 2016 Global Healthcare Conference Presentation Details

    
      
        
          Date:
        
        
           
        
        
           
        
        
          Tuesday, June 7, 2016
        
      
      
        
          Time:
        
        
        
        
        
        
          9:00 a.m. Eastern Time
        
      
      
        
          Location:
        
        
        
        
        
        
          Ballroom 5 @ Grand Hyatt Hotel New York
        
      
      
        
          Webcast:
        
        
        
        
        
        
          

LJPC Webcast Link

A live webcast of the presentation will also be available in the Investor Relations section of La Jolla’s website at www.ljpc.com. A replay of the presentation will be available on La Jolla’s website for 30 days following the event.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160606005584/en/

La Jolla Pharmaceutical CompanySandra Vedrick, 858-256-7910Senior Manager Investor Relations & Human [e-mail] M. Mulroy, 858-433-6839Chief Financial [e-mail]